Which lipid profile was recommended for enteral formulas in ARDS/ALI by the 2009 guidelines?

• A. Anti-inflammatory lipid profile
• B. High omega-6 fatty acid profile
• C. Low-fat, high-carbohydrate profile
• D. Medium-chain triglyceride enriched profile

Answer: (A)

In ARDS/ALI, the inflammatory response is a major driver of lung injury, so the fats you include in enteral formulas can influence that inflammation. An anti-inflammatory lipid profile shifts the types of fatty acids toward omega-3s (EPA and DHA) and away from omega-6s. Omega-6–derived mediators tend to promote inflammation, whereas omega-3s compete for the same enzymes and lead to less inflammatory or even pro-resolving mediators. This shift can dampen neutrophil activation, cytokine production, and capillary leak, aligning with the goal of reducing lung inflammation in ARDS/ALI. The 2009 guidelines recommended using an anti-inflammatory lipid profile in enteral formulas for these patients. In contrast, a high omega-6 profile would risk promoting inflammation, while simply lowering fat or enriching with medium-chain triglycerides addresses digestion rather than inflammatory modulation.